A direct comparison of CAR19 Treg with CAR19 CD8+ CTL administration in a xenogeneic GVHD model showed that human CAR19 CD8+ CTL–treated mice had significant weight loss, increased clinical scores, and elevated mouse IL-6 levels, in contrast with human CAR19 Tregs (43). Here, CD8A is linked to graft versus host disease.